Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Atai Life Sciences N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND OTHER LIQUID ASSETS EXPECTED TO FUND OPERATIONS INTO 2029, BEYOND ANTICIPATED TOP-LINE RESULTS FROM THE FIRST PHASE 3 CLINICAL TRIAL OF BPL-003 CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND OTHER LIQUID ASSETS EXPECTED TO FUND OPERATIONS INTO 2029, BEYOND ANTICIPATED TOP-LINE RESULTS FROM THE FIRST PHASE 3 CLINICAL TRIAL OF BPL-003

ATAI LIFE SCIENCES ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF OPTION TO PURCHASE ADDITIONAL COMMON SHARES

NEW YORK AND AMSTERDAM, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES(NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE TREATMENT OF MENTAL HEALTH DISORDERS, TODAY ANNOUNCED THE PRICING OF A REGISTERED UNDERWRITTEN OFFERING OF 23,725,000 COMMON SHARES, AT A PRICE OF $5.48 PER SHARE. ATAI HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 3,558,750 COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT. ALL COMMON SHARES TO BE SOLD IN THE OFFERING WILL BE SOLD BY ATAI.

ATAI LIFE SCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

NEW YORK AND AMSTERDAM, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE TREATMENT OF MENTAL HEALTH DISORDERS, TODAY ANNOUNCED THE COMMENCEMENT OF A PROPOSED REGISTERED UNDERWRITTEN OFFERING OF ITS COMMON SHARES. ATAI EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT. ALL COMMON SHARES TO BE SOLD IN THE OFFERING WILL BE SOLD BY ATAI. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

ATAI LIFE SCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

NEW YORK AND AMSTERDAM, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), AND BECKLEY PSYTECH LIMITED (BECKLEY PSYTECH), WHO PREVIOUSLY ANNOUNCED A PLANNED STRATEGIC COMBINATION TO CREATE A GLOBAL LEADER IN TRANSFORMATIVE MENTAL HEALTH THERAPIES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION (BTD) TO BPL-003 (MEBUFOTENIN BENZOATE) NASAL SPRAY FOR ADULT PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (TRD).

ATAI LIFE SCIENCES AND BECKLEY PSYTECH ANNOUNCE U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO BPL-003, UNDERSCORING ITS POTENTIAL IN TREATMENT-RESISTANT DEPRESSION

NEW YORK AND AMSTERDAM AND OXFORD, UNITED KINGDOM, SEPT. 23, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, AND BECKLEY PSYTECH LIMITED (BECKLEY PSYTECH), A PRIVATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE NEXT GENERATION OF MENTAL HEALTH TREATMENTS, TODAY ANNOUNCED POSITIVE DATA FROM A PROOF-OF-CONCEPT STUDY INVESTIGATING A TWO-DOSE INDUCTION REGIMEN OF BPL-003 (INTRANASAL MEBUFOTENIN BENZOATE), IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (TRD).

ATAI LIFE SCIENCES AND BECKLEY PSYTECH REPORT POSITIVE PHASE 2A DATA DEMONSTRATING IMPROVED OUTCOMES WITH A TWO-DOSE INDUCTION REGIMEN OF BPL-003 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

SOUTH SAN FRANCISCO, JULY 25, 2025 (GLOBE NEWSWIRE) -- RECOGNIFY LIFE SCIENCES, A CLINICAL-STAGE BIOTECH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COGNITIVE IMPAIRMENT, TODAY ANNOUNCED THAT ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B CLINICAL TRIAL EVALUATING INIDASCAMINE (FORMERLY RL-007) IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) DID NOT MEET ITS PRIMARY ENDPOINT.

RECOGNIFY LIFE SCIENCES PROVIDES UPDATE ON PHASE 2B TRIAL OF INIDASCAMINE IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

FINANCING CO-LED BY FERRING VENTURES S.A. AND APEIRON INVESTMENT LTD. WITH PARTICIPATION FROM NEW AND EXISTING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS, INCLUDING ALLY BRIDGE GROUP AND ADAR1 FINANCING CO-LED BY FERRING VENTURES S.A. AND APEIRON INVESTMENT LTD. WITH PARTICIPATION FROM NEW AND EXISTING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS, INCLUDING ALLY BRIDGE GROUP AND ADAR1

ATAI LIFE SCIENCES ANNOUNCES $50 MILLION PRIVATE PLACEMENT FINANCING

NEW YORK, AND AMSTERDAM AND OXFORD, UNITED KINGDOM, JULY 01, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES(NASDAQ: ATAI) (ATAI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, AND BECKLEY PSYTECH LIMITED(BECKLEY PSYTECH), A PRIVATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE NEXT GENERATION OF MENTAL HEALTH TREATMENTS, TODAY JOINTLY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE EIGHT-WEEK, QUADRUPLE-MASKED, DOSE-FINDING, CORE STAGE OF THE PHASE 2B CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF A SINGLE DOSE OF BPL-003 (INTRANASAL MEBUFOTENIN (5-MEO-DMT) BENZOATE) IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (TRD). THE STUDY ACHIEVED ITS PRIMARY ENDPOINT AS WELL AS ALL KEY SECONDARY ENDPOINTS. AT DAY 29, A SINGLE 12 MG DOSE OF BPL-003 DEMONSTRATED A STATISTICALLY SIGNIFICANT REDUCTION IN DEPRESSIVE SYMPTOMS, AS MEASURED BY THE MONTGOMERY-SBERG DEPRESSION RATING SCALE (MADRS), WITH A MEAN DECREASE OF 11.1 POINTS FROM BASELINE COMPARED TO A 5.8 POINT REDUCTION IN THE 0.3 MG COMPARATOR GROUP (P = 0.0038). FOR THE KEY SECONDARY EFFICACY ENDPOINTS, A SINGLE 8 MG DOSE OF BPL-003 ALSO SHOWED SIGNIFICANT IMPROVEMENT AT DAY 29, WITH A MEAN MADRS SCORE REDUCTION OF 12.1 POINTS (P=0.0025 FOR CHANGE VS. 0.3 MG CONTROL). NOTABLY, BOTH THE 8MG AND 12MG DOSES OF BPL-003 SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MADRS SCORES AS EARLY AS ONE DAY AFTER DOSING, WITH EFFECTS GENERALLY MAINTAINED OUT TO WEEK 8.

ATAI LIFE SCIENCES AND BECKLEY PSYTECH ANNOUNCE POSITIVE TOPLINE RESULTS FROM THE PHASE 2B STUDY OF BPL-003 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

NEW YORK AND BERLIN AND OXFORD, UNITED KINGDOM, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, AND BECKLEY PSYTECH LIMITED (BECKLEY), A PRIVATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE NEXT GENERATION OF MENTAL HEALTH TREATMENTS, TODAY ANNOUNCED A DEFINITIVE AGREEMENT UNDER WHICH ATAI AND BECKLEY PLAN TO COMBINE IN AN ALL-SHARE TRANSACTION SUBJECT TO PRE-AGREED BPL-003 (MEBUFOTENIN BENZOATE) PHASE 2B SUCCESS CRITERIA.

ATAI LIFE SCIENCES AND BECKLEY PSYTECH TO COMBINE CREATING A GLOBAL LEADER IN PSYCHEDELIC MENTAL HEALTH THERAPIES

NEW YORK AND BERLIN, MAY 29, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAMIS SCHEDULED TOPARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN JUNE:

Atai Life Sciences N.V.

ATAI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Atai Life Sciences N.V.

ATAI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATAI